Personalizing prostate cancer therapy: The way forward

Drug Discovery Today

Volumn 19, Issue 9, 2014, Pages 1483-1487

  Cetnar, Jeremy P ^a   Beer, Tomasz M ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABIRATERONE ACETATE; AFLIBERCEPT; ANTINEOPLASTIC AGENT; ATRASENTAN; BEVACIZUMAB; CALCITRIOL; CUSTIRSEN; DASATINIB; DOCETAXEL; ENZALUTAMIDE; EPITHELIAL CELL ADHESION MOLECULE; FLUORINE 18; GEFITINIB; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR VACCINE; IMATINIB; IPILIMUMAB; LENALIDOMIDE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROSTATE SPECIFIC ANTIGEN; SIPULEUCEL T; SODIUM FLUORIDE; SUNITINIB; THALIDOMIDE; TRANSCRIPTION FACTOR ERG; ZIBOTENTAN; TUMOR MARKER;

CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER THERAPY; CASTRATION RESISTANT PROSTATE CANCER; CIRCULATING TUMOR CELL; COMPUTER ASSISTED EMISSION TOMOGRAPHY; GENE FUSION; GENE MUTATION; HUMAN; MOLECULARLY TARGETED THERAPY; OVERALL SURVIVAL; PERSONALIZED MEDICINE; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POSITRON EMISSION TOMOGRAPHY; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; REVIEW; SURVIVAL RATE; SURVIVAL TIME; TREATMENT RESPONSE; CLINICAL TRIAL (TOPIC); DRUG DESIGN; GENETICS; MALE; METABOLISM; PATHOLOGY; PROCEDURES; PROGNOSIS; PROSTATIC NEOPLASMS;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; DRUG DESIGN; HUMANS; INDIVIDUALIZED MEDICINE; MALE; PROGNOSIS; PROSTATIC NEOPLASMS; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 84907854521     PISSN: 13596446     EISSN: 18785832     Source Type: Journal    
DOI: 10.1016/j.drudis.2014.07.006     Document Type: Review

References (40)

1. R. Siegel Cancer statistics CA Cancer J. Clin. 63 2013 11 30
2. H.I. Scher Increased survival with enzalutamide in prostate cancer after chemotherapy N. Engl. J. Med. 367 2012 1187 1197
3. C.J. Ryan Abiraterone in metastatic prostate cancer without previous chemotherapy N. Engl. J. Med. 368 2013 138 148
4. C.R. Pound Natural history of progression after PSA elevation following radical prostatectomy JAMA 281 1999 1591 1597
5. H.I. Scher Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group J. Clin. Oncol. 26 2008 1148 1159
6. B.J. Druker Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia N. Engl. J. Med. 344 2001 1031 1037
7. D.J. Slamon Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2 N. Engl. J. Med. 344 2001 783 792
8. M.S. Tsao Erlotinib in lung cancer - molecular and clinical predictors of outcome N. Engl. J. Med. 353 2005 133 144
9. A.T. Shaw Crizotinib versus chemotherapy in advanced ALK-positive lung cancer N. Engl. J. Med. 368 2013 2385 2394
10. A.D. Roth Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993 SAKK 60-00 trial J. Clin. Oncol. 28 2010 466 474
11. P.B. Chapman Improved survival with vemurafenib in melanoma with BRAF V600E mutation N. Engl. J. Med. 364 2011 2507 2516
12. C. Kumar-Sinha Recurrent gene fusions in prostate cancer Nat. Rev. Cancer 8 2008 497 511
13. S. Roychowdhury, and A.M. Chinnaiyan Advancing precision medicine for prostate cancer through genomics J. Clin. Oncol. 31 2013 1866 1873
14. A.J. Armstrong Biomarkers in the management and treatment of men with metastatic castration-resistant prostate cancer Eur. Urol. 61 2012 549 559
15. S. Halabi Progression-free survival as a predictor of overall survival in men with castrate-resistant prostate cancer J. Clin. Oncol. 27 2009 2766 2771
16. M.E. Taplin Effect of neoadjuvant abiraterone acetate (AA) plus leuprolide acetate (LHRHa) on PSA, pathological complete response (pCR), and near pCR in localized high-risk prostate cancer (LHRPC): results of a randomized phase II study J. Clin. Oncol. 30 2012 abstr. 4521
17. K.N. Chi A phase I pharmacokinetic and pharmacodynamic study of OGX-011, a 2′-methoxyethyl antisense oligonucleotide to clusterin, in patients with localized prostate cancer J. Natl. Cancer Inst. 97 2005 1287 1296
18. R.R. McKay Rationale for and review of neoadjuvant therapy prior to radical prostatectomy for patients with high-risk prostate cancer Drugs 73 2013 1417 1430
19. C.E. Spritzer Bone marrow biopsy: RNA isolation with expression profiling in men with metastatic castration-resistant prostate cancer - factors affecting diagnostic success Radiology 269 2013 816 823
20. W.J. Allard Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases Clin. Cancer Res. 10 2004 6897 6904
21. D. Issadore Ultrasensitive clinical enumeration of rare cells ex vivo using a micro-hall detector Sci. Transl. Med. 4 2012 141ra192
22. J.S. de Bono Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer Clin. Cancer Res. 14 2008 6302 6309
23. M.A. Leversha Fluorescence in situ hybridization analysis of circulating tumor cells in metastatic prostate cancer Clin. Cancer Res. 15 2009 2091 2097
24. D.R. Shaffer Circulating tumor cell analysis in patients with progressive castration-resistant prostate cancer Clin. Cancer Res. 13 2007 2023 2029
25. H.I. Scher Evaluation of circulating tumor cell (CTC) enumeration as an efficacy response biomarker of overall survival (OS) in metastatic castration-resistant prostate cancer (mCRPC): planned final analysis (FA) of COU-AA-301, a randomized double-blind, placebo-controlled phase III study of abiraterone acetate (AA) plus low-dose prednisone (P) post docetaxel J. Clin. Oncol. 29 2011 abstr. LBA4517
26. H. Schirrmeister Prospective evaluation of the clinical value of planar bone scans, SPECT, and (18)F-labeled NaF PET in newly diagnosed lung cancer J. Nucl. Med. 42 2001 1800 1804
27. E.Y. Yu Correlation of 18F-fluoride PET response to dasatinib in castration-resistant prostate cancer bone metastases with progression-free survival: preliminary results from ACRIN 6687 J. Clin. Oncol. 31 2013 abstr. 5003
28. K.A. Autio Evaluating 18F-16B-fluoro-5α-dihydrotestosterone (FDHT) and FDG-PET as a measure of disease progression in metastatic castration resistant prostate cancer (mCRPC) J. Clin. Oncol. 31 2013 abstr. 5090
29. P.W. Kantoff Sipuleucel-T immunotherapy for castration-resistant prostate cancer N. Engl. J. Med. 363 2010 411 422
30. C.J. Ryan Serum androgens as prognostic biomarkers in castration-resistant prostate cancer: results from an analysis of a randomized phase III trial J. Clin. Oncol. 31 2013 2791 2798
31. E.S. Kim The BATTLE trial: personalizing therapy for lung cancer Cancer Discov. 1 2011 44 53
32. A.D. Barker I-SPY 2: an adaptive breast cancer trial design in the setting of neoadjuvant chemotherapy Clin. Pharmacol. Ther. 86 2009 97 100
33. H.I. Scher Randomized, open-label phase III trial of docetaxel plus high-dose calcitriol versus docetaxel plus prednisone for patients with castration-resistant prostate cancer J. Clin. Oncol. 29 2011 2191 2198
34. E. Small A phase III trial of GVAX immunotherapy for prostate cancer in combination with docetaxel versus docetaxel plus prednisone in symptomatic, castration-resistant prostate cancer (CRPC) GU CA Symp. 2009 abstr. 07
35. D.I. Quinn Docetaxel and atrasentan versus docetaxel and placebo for men with advanced castration-resistant prostate cancer (SWOG S0421): a randomised phase 3 trial Lancet Oncol. 14 2013 893 900
36. K.S. Fizazi Phase III, randomized, placebo-controlled study of docetaxel in combination with zibotentan in patients with metastatic castration-resistant prostate cancer J. Clin. Oncol. 31 2013 1740 1747
37. D.P. Petrylak A phase 3 study to evaluate the efficacy and safety of docetaxel and prednisone (DP) with or without lenalidomide (LEN) in patients with castrate-resistant prostate cancer (CRPC): the MAINSAIL trial Ann. Oncol. 23 2012 abstr. LBA24
38. W.K. Kelly Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401 J. Clin. Oncol. 30 2012 1534 1540
39. J.C. Araujo Docetaxel and dasatinib or placebo in men with metastatic castration-resistant prostate cancer (READY): a randomised, double-blind phase 3 trial Lancet Oncol. 14 2013 1307 1316
40. I. Tannock Aflibercept versus placebo in combination with docetaxel/prednisone for first-line treatment of men with metastatic castration-resistant prostate cancer (mCRPC): results from the multinational phase III trial (VENICE) J. Clin. Oncol. 31 2013 abstr. 13